Mark A. Hlatky, MDProfessor of Health Research and Policy and of Medicine (Cardiovascular Medicine) and Stanford Health Policy Fellow
Hlatky's coronary disease treatment comparison study continues to capture global press coveragein the news
Faculty fellow Mark Hlatky continues to garner media coverage for his Lancet article comparing coronary artery bypass surgery and percutaneous coronary interventions for multivessel disease. Featured in hundreds of publications worldwide, Hlatky is also interviewed in the April 4th Lancet podcast.
Taking prescription beta blocker or statin drugs may boost the chances of having only mild chest pain instead of a heart attack as the first symptom of heart disease, according to a study co-authored by CHP/PCOR researchers.
Read more »
A study by CHP/PCOR researchers, published in the Oct. 6 issue of the New England Journal of Medicine, finds that the implantable cardioverter defibrillator - one of the most expensive medical devices on the market - is a relatively cost-effective way to help prevent sudden cardiac deaths in certain patients.
Read more »
in the news: New York Times on August 2, 2005
CHP/PCOR fellow Mark Hlatky provides comment for an Aug. 2 New York Times article on mounting concerns about the high cost and possible overuse of implantable cardiac defibrillators as use of the device expands. Read more »
in the news: St. Louis Post-Dispatch on September 25, 2004
CHP/PCOR fellows Laurence C. Baker and Mark A. Hlatky provide comment for a lengthy St. Louis Post-Dispatch article that examines the role of medical technology in the nation's rising healthcare costs, and the need to balance individual benefits and societal costs when making patient care decisions. Read more »